NCT01982643View on ClinicalTrials.gov

Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Methamphetamine Use Disorder
Interventions
DRUG

naltrexone plus bupropion

Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.

Trial Locations (3)

75208

Nexus Recovery Center, Dallas

90025

UCLA Integrated Substance Abuse Programs, Los Angeles

96813

University of Hawaii, Honolulu

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

The Emmes Company, LLC

INDUSTRY

lead

Walter Ling

OTHER

NCT01982643 - Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder | Biotech Hunter | Biotech Hunter